Abstract
Development of antiviral agents that target the hepatitis C virus (HCV) has improved the success and tolerability of treatment, especially for patients with HCV genotype 1 infection. The new treatment options mean that clinicians are better able to prevent complications from chronic HCV infection. The field of direct-acting antiviral therapies for HCV infection continues to advance at a rapid pace, and many more potential treatment regimens are being investigated. This article presents a summary of the current treatments available for patients infected with HCV genotype 1 and looks ahead to those that may play a role in the future.
Original language | English (US) |
---|---|
Pages (from-to) | 825-843 |
Number of pages | 19 |
Journal | Gastroenterology Clinics of North America |
Volume | 44 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2015 |
Keywords
- Cirrhosis
- Hepatitis
- Hepatitis C
- Ledipasvir antiviral
- Simeprevir
- Sofosbuvir
ASJC Scopus subject areas
- Gastroenterology